Evidence map›Paper›PMID 42812057›Full record

Trial reportNan fang yi ke da xue xue bao = Journal of Southern Medical University

[

Ai Qian, Chuanbing Huang, Yawen Zhu, Kexin Hu, Xinran Song, Yuxiang Xu

Abstract readRandomized Controlled TrialEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nan fang yi ke da xue xue bao = Journal of Southern Medical University. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ai QianFirst Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230031, China.
Chuanbing HuangFirst Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230031, China.
Yawen ZhuFirst Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230031, China.
Kexin HuFirst Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230031, China.
Xinran SongFirst Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230031, China.
Yuxiang XuFirst Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei 230031, China.

Funding

National Natural Science Foundation of China 82574970
6 · The paper itself

Abstract

objectivesTo investigate the mechanism of

methodsPublic databases were used to screen the targets of QJZG, SLE and renal damage. An active ingredient-target network and a protein-protein interaction network were constructed followed by molecular docking. Sixty-two SLE patients were randomized into QJZG treatment group and control group (

resultsThree key active ingredients of QJZG (quercetin, kaempferol, and 7-O-methylisoflavanone) and 9 core targets were identified, and the target genes were enriched in the TNF, HIF-1, and mTOR pathways. Molecular docking showed strong binding of the active compounds of QJZG with HIF-1α and mTOR. In SLE patients, QJZG treatment significantly improved their renal function, regulated the immune function (increasing CD4

conclusionsQJZG alleviated renal damage in SLE patients through a mechanism involving multiple components and targets. The active ingredients of QJZG regulate macrophage polarization possibly by activating the AMPK/ULK1 pathway via binding to their targets including HIF-1α and mTOR.

Indexed as

Drugs, Chinese HerbalKidneyLupus Erythematosus, SystemicMacrophagesAdultAMP-Activated Protein KinasesAutophagy-Related Protein-1 HomologFemaleHumansIntracellular Signaling Peptides and ProteinsMaleMolecular Docking SimulationSignal TransductionAMP-Activated Protein KinasesAutophagy-Related Protein-1 HomologDrugs, Chinese HerbalIntracellular Signaling Peptides and ProteinsULK1 protein, humanAMPK/ULK1 signaling pathwayM1/M2 polarization of macrophagesnetwork pharmacologyQihuang Jianpi Zishen Granulessystemic lupus erythematosus

Identifiers

PMID42812057
PMCPMC13624994

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.